Answers are grounded in this paper and cite their sources.
The Normal Hematocrit Trial (NHT) was the largest trial of epoetin randomizing 1265 hemodialysis patients with cardiac disease to lower (9–11g/dl) or higher (13–15g/dl) hemoglobin (Hgb), hypothesizing that higher Hgb would reduce mortality, and improve survival and quality of life. The trial was terminated early, and a 1998 publication reported that targeting higher hematocrit levels led to an insignificant increase in the primary end points (death or myocardial infarct), or risk ratio 1.3, 95% confidence interval (CI), 0.9–1.90, but the P-value was not given, and all-cause death risk was not reported. A higher target reportedly did not increase hospitalization rates, but did significantly improve the ‘physical function’ domain of quality of life. Comparing the 1996 Food and Drug Administration (FDA)-filed clinical trial report to the 1998 publication, however, found several discrepancies. Among these, the 1998 article reported interim trial results with only the adjusted CI but did not state that the unadjusted CIs were 99.912th percentile, and despite being a secondary end point, reported only the association of achieved Hgb with higher quality of life score. Randomization to the higher target had actually increased the risk for the primary end point (risk ratio 1.28, 95% CI=1.06–1.56; P=0.0112; 99.92% CI=0.92–1.78), the risk of death (risk ratio 1.27, 95% CI=1.04–1.54), non-access thrombotic events (P=0.041), and hospitalization rate (P=0.04), while ‘physical function’ did not improve (P=0.88). Hence, disclosure of these results in the 1998 publication or access to the FDA-filed report on the NHT in the late 1990s would likely have led to earlier concerns about epoetin safety and greater doubts about its benefits. The Normal Hematocrit Trial (NHT) was the largest trial of epoetin randomizing 1265 hemodialysis patients with cardiac disease to lower (9–11g/dl) or higher (13–15g/dl) hemoglobin (Hgb), hypothesizing that higher Hgb would reduce mortality, and improve survival and quality of life. The trial was terminated early, and a 1998 publication reported that targeting higher hematocrit levels led to an insignificant increase in the primary end points (death or myocardial infarct), or risk ratio 1.3, 95% confidence interval (CI), 0.9–1.90, but the P-value was not given, and all-cause death risk was not reported. A higher target reportedly did not increase hospitalization rates, but did significantly improve the ‘physical function’ domain of quality of life. Comparing the 1996 Food and Drug Administration (FDA)-filed clinical trial report to the 1998 publication, however, found several discrepancies. Among these, the 1998 article reported interim trial results with only the adjusted CI but did not state that the unadjusted CIs were 99.912th percentile, and despite being a secondary end point, reported only the association of achieved Hgb with higher quality of life score. Randomization to the higher target had actually increased the risk for the primary end point (risk ratio 1.28, 95% CI=1.06–1.56; P=0.0112; 99.92% CI=0.92–1.78), the risk of death (risk ratio 1.27, 95% CI=1.04–1.54), non-access thrombotic events (P=0.041), and hospitalization rate (P=0.04), while ‘physical function’ did not improve (P=0.88). Hence, disclosure of these results in the 1998 publication or access to the FDA-filed report on the NHT in the late 1990s would likely have led to earlier concerns about epoetin safety and greater doubts about its benefits. There has been controversy over the risks and benefits of erythropoietic-stimulating agent (ESA) therapy since the completion of the Normal Hematocrit Trial (NHT) in 1996 and its publication in 1998.1.Besarab A. Bolton W.K. Browne J.K. et al.The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [see comment].N Eng J Med. 1998; 339: 584-590Crossref PubMed Scopus (1879) Google Scholar The NHT remains the largest randomized trial of ESA in hemodialysis patients. It treated patients with clinical evidence of heart failure or ischemic heart disease with epoetin (an ESA) to a target hematocrit of 30±3% vs. 42±3%. Hematocrit was calculated by multiplying the measured hemoglobin (Hgb) level by three. A majority of the US dialysis patients have ischemic heart disease or heart failure.2.Stack A.G. Bloembergen W.E. A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients.Am J Kidney Dis. 2001; 38: 992-1000Abstract Full Text Full Text PDF PubMed Scopus (156) Google Scholar, 3.Stack A.G. Bloembergen W.E. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study.J Am Soc Nephrol. 2001; 12: 1516-1523PubMed Google Scholar, 4.Goodkin D.A. Bragg-Gresham J.L. Koenig K.G. et al.Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS).J Am Soc Nephrol. 2003; 14: 3270-3277Crossref PubMed Scopus (628) Google Scholar Therefore, the NHT represented an important assessment of the risks and benefits of higher Hgb for the majority of dialysis patients. The NHT was stopped early because of a trend toward increased deaths and nonfatal MI in the high-Hgb target arm.1.Besarab A. Bolton W.K. Browne J.K. et al.The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [see comment].N Eng J Med. 1998; 339: 584-590Crossref PubMed Scopus (1879) Google Scholar Although the NHT trial results demonstrated satisfactory outcomes with a Hgb target of 9–11g/dl, subsequent nephrology anemia guidelines in 1997 and 2001 recommended a Hgb target of 11–12g/dl when prescribing an ESA.5.National Kidney Foundation-Dialysis Outcomes Quality Initiative NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure.Am J Kidney Dis. 1997; 30: S192-S240PubMed Google Scholar,6.National Kidney Foundation. KDOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease, 2000.Am J Kidney Dis. 2001; 37: S182-S238PubMed Google Scholar This was largely based on studies suggesting other benefits from somewhat higher Hgb, including improvements in health-related quality of life (HRQOL). The NHT publication stated that higher Hgb had significantly increased scores in the ‘physical function’ domain of HRQOL. As the NHT is the largest trial of ESAs in hemodialysis, the report of improvements in physical function via higher Hgb had a great impact on clinical guidelines that attempted to balance the risks and benefits of ESA therapy. By 2006, the improvement in HRQOL observed in the NHT was of central importance, as the US and European Renal guidelines recommended that all patients with chronic kidney disease (CKD) should have Hgb maintained at 11g/dl or higher.7.KDOQI; National Kidney Foundation KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.Am J Kidney Dis. 2006; 47: S11-S145PubMed Google Scholar,8.Locatelli F. Aljama P. Barany P. et al.Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure.Nephrol PubMed Scopus Google Scholar The US Kidney Quality that of is a the of treatment National Kidney Foundation KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.Am J Kidney Dis. 2006; 47: S11-S145PubMed Google Scholar in 2006, in and other reported increased and events and death with ESA when targeting higher et and mortality with and for the treatment of PubMed Scopus Google Scholar, et of anemia with epoetin in chronic kidney Eng J Med. 2006; PubMed Scopus Google Scholar, F. et of hemoglobin level in patients with chronic kidney disease and Eng J Med. 2006; PubMed Scopus Google Scholar, Food and Drug Scholar the US recommended lower Hgb and when Food and Drug about an Scholar the compared treatment to ESA therapy targeting a Hgb of demonstrated that ESA therapy in cardiac events or a improvement in quality of and an increased risk of and and et trial of in and chronic kidney Eng J Med. PubMed Scopus Google Scholar the Food and Drug Administration that ESAs to target a Hgb level of greater 11g/dl the risk of events and has not been to Drug to improve the of in chronic kidney Scholar This is in with the NHT results from reported that a higher Hgb target HRQOL and increased to the results of the NHT in 1998 were and the in renal anemia the NHT report by with the in 1996 a of and compared the primary and secondary HRQOL results in the clinical trial report with the 1998 The trial randomized 1265 the 1998 publication and of the on the patients who were of the interim by the safety A. Bolton W.K. Browne J.K. et al.The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [see comment].N Eng J Med. 1998; 339: 584-590Crossref PubMed Scopus (1879) Google A. The Normal Hematocrit Eng J Med. PubMed Scopus Google Scholar The clinical trial report on that on the 1265 patients did not the The primary results on the were reported in a in A. The Normal Hematocrit Eng J Med. PubMed Scopus Google Scholar The in the primary and secondary end points and events the 1998 publication and the are in the and the safety on ESAs in with the NHT The the primary end point are to the 1998 report and the adjusted 95% confidence and not the P-value for the would have been A. Bolton W.K. Browne J.K. et al.The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [see comment].N Eng J Med. 1998; 339: 584-590Crossref PubMed Scopus (1879) Google A. The Normal Hematocrit Eng J Med. PubMed Scopus Google Scholar As in the on and the unadjusted CIs for were at the interim and 99.92% at study As in the of the publication, these CIs were adjusted to for by the safety the treatment with to the primary end point and all-cause death are by the unadjusted but to the by the safety the trial early the an insignificant and the reported only the unadjusted 95% and the trial results as Drug to improve the of in chronic kidney of 1998 and to the FDA-filed NHT Clinical Trial of Clinical Trial interim on 1996 on interim on 1996 on end point CI not CI adjusted for the interim P-value for at interim was at trial for risk for the primary end point was 1.28, 95% CI and for all-cause death was 1.27, 95% CI P-value for at interim was at P-value for at interim was at trial for risk for the primary end point was 1.28, 95% CI and for all-cause death was 1.27, 95% CI vs. by vs. by for 95% CI of function domain increased by point for increase in the hematocrit of improvement over or access vs. thrombotic access vs. thrombotic vs. trial of to the Clinical Trial the results on 1265 patients trial on the results on 1265 patients trial on end point P-value not The 95% CI were adjusted for the interim with the of the of confidence P-value for at was at trial for risk for the primary end point was 1.28, 95% CI and for all-cause death was 1.27, 95% CI confidence Food and Drug myocardial not The P-value for at interim was at The P-value for at was at The trial for risk for the primary end point was 1.28, 95% CI and for all-cause death was 1.27, 95% CI in a new confidence Food and Drug myocardial not The 1998 publication that were in the of ischemic of the that epoetin to anemia increase thrombotic the on that was a of thrombotic and but myocardial and access to the patients randomized to the higher target significantly thrombotic vs. The HRQOL was measured at and at patients had reported at point in the HRQOL results the 1998 publication, were and patients in the trial at and The 1998 publication reported the HRQOL as on the at increased by point for increase in the hematocrit an increase in the hematocrit from to was with a increase of points in the on the There were in the scores on the other The on the physical function as in the and as in the low the scores for ‘physical function’ domain at and with the epoetin and for at The that were in scores or over of the the the was the primary for primary of in the the for over A target target end points end points health-related quality of and values were a There are in scores in and in a new health-related quality of life. and values were a There are in scores in and the results in the and the scores for the at point, by treatment The the HRQOL on as were A and scores at and scores did not significantly over scores for primary end points physical and and secondary end points over A target target function function function health-related quality of are in scores at and scores did not significantly over and values were a and in a new health-related quality of life. There are in scores at and scores did not significantly over and values were a and to the on in hospitalization were to compared the and the and the 1998 publication reported in hospitalization when compared The hospitalization to the 1998 publication, but on and the to hospitalization results in the for to that hematocrit patients higher compared to A hematocrit patients for of but the CI to This report several the publication of the NHT trial in 1998 and the with the in The NHT was to the of targeting higher A. Bolton W.K. Browne J.K. et al.The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [see comment].N Eng J Med. 1998; 339: 584-590Crossref PubMed Scopus (1879) Google Scholar mortality and the primary end point of mortality nonfatal myocardial were significantly higher in the target results were not a to the as the on that a for the trial was an risk of mortality among the effects of of anemia in dialysis The publication these results as because of of the CIs for by the safety and was by the A. Bolton W.K. Browne J.K. et al.The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [see comment].N Eng J Med. 1998; 339: 584-590Crossref PubMed Scopus (1879) Google D.A. The normal hematocrit cardiac trial PubMed Scopus Google Scholar results were not reported in the 1998 publication on the interim or in a in the trial A. The Normal Hematocrit Eng J Med. PubMed Scopus Google Scholar The in ESA that the NHT found significantly higher risk when targeting higher Hgb for all-cause mortality 95% CI and the primary end point 95% CI CIs are not Drug to improve the of in chronic kidney Scholar the of the compared with a Hgb target of 9–11g/dl, targeting the risk of and and other thrombotic events (P=0.04), the to hospitalization (P=0.04), and to increase all-cause mortality 95% CI The was a in the of patients HRQOL did not The NHT remains the largest ESA trial in the hemodialysis The trial with and with with a of about and a on dialysis of to of the US dialysis A. Bolton W.K. Browne J.K. et al.The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [see comment].N Eng J Med. 1998; 339: 584-590Crossref PubMed Scopus (1879) Google Renal of Renal in the United National of National of and and Kidney Scholar a majority of the US dialysis patients have cardiac as did all the patients in the A.G. Bloembergen W.E. A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients.Am J Kidney Dis. 2001; 38: 992-1000Abstract Full Text Full Text PDF PubMed Scopus (156) Google Scholar, 3.Stack A.G. Bloembergen W.E. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study.J Am Soc Nephrol. 2001; 12: 1516-1523PubMed Google Scholar, 4.Goodkin D.A. Bragg-Gresham J.L. Koenig K.G. et al.Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS).J Am Soc Nephrol. 2003; 14: 3270-3277Crossref PubMed Scopus (628) Google Scholar As higher Hgb with lower cardiac rates, and higher was that Hgb would to The NHT was to A. Bolton W.K. Browne J.K. et al.The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [see comment].N Eng J Med. 1998; 339: 584-590Crossref PubMed Scopus (1879) Google Scholar The results suggesting from targeting higher Hgb represented the evidence of safety with the of early of the NHT but publication of the the National Kidney Dialysis Outcomes Quality Initiative guidelines recommended a Hgb of 11–12g/dl when an ESA in with patients Kidney Foundation-Dialysis Outcomes Quality Initiative NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure.Am J Kidney Dis. 1997; 30: S192-S240PubMed Google Scholar The 1997 KDOQI was that the NHT had been terminated early because the target a greater of nonfatal myocardial or the Kidney Foundation-Dialysis Outcomes Quality Initiative NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure.Am J Kidney Dis. 1997; 30: S192-S240PubMed Google Scholar The 1997 KDOQI and 2001 did not have the evidence and that are to Kidney Foundation-Dialysis Outcomes Quality Initiative NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure.Am J Kidney Dis. 1997; 30: S192-S240PubMed Google Scholar,6.National Kidney Foundation. KDOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease, 2000.Am J Kidney Dis. 2001; 37: S182-S238PubMed Google Scholar and of quality were in of There was evidence of safety with ESAs in patients with renal disease or other was a that higher Hgb was benefits in and based on and trial the 2001 guidelines and of evidence to a Hgb target of 11–12g/dl when Kidney Foundation. KDOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease, 2000.Am J Kidney Dis. 2001; 37: S182-S238PubMed Google Scholar The 2001 a lower rate of hospitalization when targeting higher Hgb, would have been by publication of the results Kidney Foundation. KDOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease, 2000.Am J Kidney Dis. 2001; 37: S182-S238PubMed Google Scholar is that of the results in would have significantly the 1997 or the 2001 KDOQI guidelines because of the of evidence of from by 2006, was evidence that ESAs increased risks and increased deaths in et and mortality with and for the treatment of PubMed Scopus Google Scholar of the earlier benefits from targeting normal Hgb, as of had to in randomized et of and anemia in incident hemodialysis patients heart Am Soc Nephrol. PubMed Scopus Google Scholar the KDOQI Anemia guidelines were of National Kidney Foundation KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.Am J Kidney Dis. 2006; 47: S11-S145PubMed Google Scholar clinical were the quality of trial was and results were evidence the of of the evidence the a Clinical Practice that patients with should or National Kidney Foundation KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.Am J Kidney Dis. 2006; 47: S11-S145PubMed Google Scholar This was a from had anemia A Clinical Practice practice the for clinical to A. et evidence and for clinical practice guidelines in A from kidney outcomes 2006; Full Text Full Text PDF PubMed Scopus Google Scholar The stated that the level should or the higher with lower is a the of treatment in the National Kidney Foundation KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.Am J Kidney Dis. 2006; 47: S11-S145PubMed Google Scholar The KDOQI Hgb target was based on of trial The in of HRQOL by the largest was the 1998 NHT publication National Kidney Foundation KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.Am J Kidney Dis. 2006; 47: S11-S145PubMed Google Scholar The NHT results were as with higher by point for point increase in as from the 1998 National Kidney Foundation KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.Am J Kidney Dis. 2006; 47: S11-S145PubMed Google Scholar of the other reported improvement in HRQOL when targeting higher vs. lower Study and quality of life and of patients receiving PubMed Google A. et of early and late with epoetin on among patients with chronic kidney disease or results of a randomized clinical Am Soc Nephrol. PubMed Scopus Google Scholar The other to hemodialysis had results improvement in et of and anemia in incident hemodialysis patients heart Am Soc Nephrol. PubMed Scopus Google et of hemoglobin levels in hemodialysis patients with Full Text Full Text PDF PubMed Scopus Google Scholar found improvement in with higher Hgb but did improvements on other HRQOL et of hemoglobin levels in hemodialysis patients with Full Text Full Text PDF PubMed Scopus Google Scholar the other trial found an improvement in domain scores that for the of the et of and anemia in incident hemodialysis patients heart Am Soc Nephrol. PubMed Scopus Google Scholar This trial reported a higher rate vs. with targeting higher et of and anemia in incident hemodialysis patients heart Am Soc Nephrol. PubMed Scopus Google Scholar of and patients were but the of these did not treatment in National Kidney Foundation KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.Am J Kidney Dis. 2006; 47: S11-S145PubMed Google Scholar The that evidence the that patients treated to a target greater likely benefits with or increase in compared with treatment at lower National Kidney Foundation KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.Am J Kidney Dis. 2006; 47: S11-S145PubMed Google Scholar The results and is likely that the KDOQI would have been and would not have as a Clinical Practice from of hemoglobin target on are from the KDOQI Anemia evidence and from only are vs. low hemoglobin target HRQOL hemoglobin target of 11g/dl or et A. Bolton W.K. Browne J.K. et al.The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [see comment].N Eng J Med. 1998; 339: 584-590Crossref PubMed Scopus (1879) Google all had heart failure or vs. physical function to 1998 Study and quality of life and of patients receiving PubMed Google trial had a treatment had improvements in HRQOL compared with all had or vs. et et of hemoglobin levels in hemodialysis patients with Full Text Full Text PDF PubMed Scopus Google of vs. in et et of and anemia in incident hemodialysis patients heart Am Soc Nephrol. PubMed Scopus Google or vs. significantly increased risk of et A. et of early and late with epoetin on among patients with chronic kidney disease or results of a randomized clinical Am Soc Nephrol. PubMed Scopus Google and or chronic or vs. coronary chronic kidney heart health-related quality of are from the KDOQI Anemia evidence and from only are This trial had a treatment had improvements in HRQOL compared with in a new coronary chronic kidney heart health-related quality of is a by the 1998 the the 1998 publication stated that HRQOL would as a secondary end point, but the results a of the association of achieved hematocrit to ‘physical function’ a treatment the association of higher Hgb with higher ‘physical the 1998 publication as an of the of the improvement a of hematocrit values of and the hematocrit values that to the in the This the that being randomized to a hematocrit of the ‘physical function’ by and that the P-value to the treatment The results from the that to the higher target did not improve of HRQOL. an Hgb of 11–12g/dl in hemodialysis patients with cardiac as KDOQI recommended in a would to a or insignificant in observed in the trial on an target with ESAs the observed with higher The trial in patients with and ESA treatment to target Hgb to vs. and found an increased risk of events and death with the higher et of anemia with epoetin in chronic kidney Eng J Med. 2006; PubMed Scopus Google Scholar The trial reported a increase in thrombotic events and with ESA and studies the that ESA et trial of in and chronic kidney Eng J Med. PubMed Scopus Google et increase the risk of in patients with chronic kidney Full Text Full Text PDF PubMed Scopus Google Scholar Therefore, is the Hgb target while ESA a target 11g/dl but to benefits and dialysis patients have significantly higher scores on the reported in the and improvement in with higher et of and anemia in incident hemodialysis patients heart Am Soc Nephrol. PubMed Scopus Google and of health-related quality of life in patients receiving treatment for Full Text Full Text PDF PubMed Scopus Google Scholar in the NHT at a increase in Hgb and of the mortality was improvement in or other HRQOL KDOQI and in the nephrology the results of of higher Hgb as of quality of the the results that the largest Hgb that effects were and et for a Eng J Med. PubMed Scopus Google Scholar HRQOL improvements were in trial that significantly increased the risk of events or A. Bolton W.K. Browne J.K. et al.The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [see comment].N Eng J Med. 1998; 339: 584-590Crossref PubMed Scopus (1879) Google Scholar, et of anemia with epoetin in chronic kidney Eng J Med. 2006; PubMed Scopus Google Scholar, et trial of in and chronic kidney Eng J Med. PubMed Scopus Google Scholar the has stated that ESAs to target a Hgb level of greater 11g/dl has not been to Kidney Foundation. KDOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease, 2000.Am J Kidney Dis. 2001; 37: S182-S238PubMed Google Scholar of the of the 1998 publication were and had access to the to the other had only and of is and of randomized trial all should to the clinical trial report and in that the a of the safety and all clinical trial with the on all should a or of trial should trial on all studies from the via the of trial report should and by who have to the or the the of these results on the in hemodialysis patients with ischemic heart disease or heart are benefits from targeting Hgb to 11g/dl with A of was on for the report on the NHT by with the of the trial in The was on that are from the are in in publication, by the or the The was to and the and of the report are by and NHT Trial in the The report a to the for the 1996 clinical study report on the primary and secondary end points of the and the results as reported in the were compared with the 1998 publication and to the NHT in the National Kidney Kidney Outcomes Quality Initiative anemia guidelines in and The trial and treatment are in the A. Bolton W.K. Browne J.K. et al.The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [see comment].N Eng J Med. 1998; 339: 584-590Crossref PubMed Scopus (1879) Google Scholar hemodialysis patients with clinical evidence of heart disease of heart failure or ischemic heart who were receiving epoetin and had Hgb of were randomized to a higher or lower Hgb The higher target a increase in epoetin by at as to a target of randomized to the lower target had epoetin adjusted to a Hgb level of to the and hematocrit was calculated by multiplying the Hgb level by three. to the primary of study was to the effects of the hematocrit and on and mortality in dialysis patients with cardiac disease who were receiving therapy. Quality of life was The primary end point was death and nonfatal myocardial end points all-cause mortality MI all-cause congestive heart failure coronary artery coronary quality of and as as in cardiac mortality and all-cause hospitalization were compared treatment the and secondary end points as and were compared The stated on and Quality of a Outcomes Study at and The is a outcomes that has been in studies of primary HRQOL end points for study were the the physical function and the end points were the the physical the and the function the was calculated for an The was for The stated on that a of thrombotic was because was the of epoetin to anemia and these
No takes yet. Share an insight, caveat, or question.
Daniel W. Coyne (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: